NCT01909453 2026-02-27
COLUMBUS
Pfizer
Phase 3 Completed
Clinical Trials
12 trialsNCT05304546 2025-07-22
MK3475-C01
Sheba Medical Center
Phase 2 Completed
NCT03898908 2025-05-21
EBRAIN-MEL
Grupo Español Multidisciplinar de Melanoma
Phase 2 Completed
NCT05340621 2025-03-07
NAUTILUS: OKI-179 Plus Binimetinib in Patients with Advanced Solid Tumors in the RAS Pathway (Phase 1b) and NRAS-mutated Melanoma (Phase 2)
OnKure, Inc.
Phase 1/2 Completed
NCT05260684 2025-03-06
OCEANMIST
Pfizer
Completed
NCT03864042 2024-09-27
Pharmacokinetic Drug-drug Interaction Study of Encorafenib and Binimetinib on Probe Drugs in Patients With BRAF V600-mutant Melanoma or Other Advanced Solid Tumors
Pfizer
Phase 1 Completed
NCT05810740 2024-09-19
Bioequivalence Binimetinib 3 x 15 mg and 45 mg Formulations
Pierre Fabre Medicament
Phase 1 Completed
NCT02631447 2024-06-07
SECOMBIT
Fondazione Melanoma Onlus
Phase 2 Completed
NCT02159066 2024-03-05
LOGIC-2
Pfizer
Phase 2 Completed
NCT01320085 2024-01-24
A Phase II Study of Single Agent MEK162 in Patients With Advanced Melanoma
Pfizer
Phase 2 Completed
NCT01763164 2021-03-22
Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Unresectable or Metastatic NRAS Mutation-positive Melanoma
Pfizer
Phase 3 Completed
NCT02902042 2021-02-16
IMMU-TARGET
University Hospital, Essen
Phase 1/2 Completed